Objective To observe the efficacy of small doses of oral Aspirin combined Iressa and Iressa in treating the non-small cell lung cancer, and analyze that contrastively. Methods 56 non-small cell lung cancer patients admitted in our department from November 2010 to November 2012 were collected and randomly divided into two groups. 28 patients in the research group were given small doses of oral Aspirin combined with Iressa for chemotherapy, and 28 patients in the control group were given Iressa for chemotherapy. The chemotherapy was not terminated until the disease progressed or the side effects could not be tolerated. The curative effect and adverse reactions of the two different schemes for tumor after 2, 4, 6 cycles of treatment were observed, and one-year survival rate of both groups of patients was observed through follow-up, and the data of the two groups were compared, analyzed and evaluated. Results The effective rate of the research group was 14.3%, and that of the control group was 10.7%, the difference was statistically significant (P<0.05); the disease control rate of the research group was 78.6%, and that of the control group was 75%, the difference was not statistically significant (P>0.05); The side effects of Iressa mainly were a transient loss of appetite, mild rash and diarrhea. The incidence of a transient loss of appetite and mild rash in the research group was 32.1%, 39.3%, respectively, obviously lower than that (60.7% and 67.9%, respectively) in the control group, the differences were statisti_cally significant (P<0.05); the one-year survival rate in the two groups was 50% and 39.3%, respectively, the difference was not statistically significant (P>0.05). Conclusion The treatment of small doses of oral Aspirin combined with Iressa has better clinical efficacy than the treatment of Iressa for non-small cell lung cancer. Aspirin can decrease the high blood coagulation state, improve the treatment efficiency and survival time in tumor patients, which also can reduce the time of tumor progression, thereby improv_ing the quality of life of tumor patients.%目的：探讨阿司匹林小剂量口服联合易瑞沙与单药易瑞沙治疗非小细胞肺癌的疗效，并进行对比分析。方法对该院收集2010年11月―2012年11月期间非小细胞肺癌患者56例，随机分为两组，其中28例研究组给予阿司匹林小剂量口服联合易瑞沙化疗，对照组28例单用易瑞沙化疗，直至出现病情进展或不良反应不能耐受而终止化疗，观察两种不同方案治疗两、四、六周期后的肿瘤疗效、不良反应以及随访观察1年生存率进行对比分析评定。结果研究组的有效率为14.3%，对照组为10.7%，差异有统计学意义(P<0.05)；研究组的疾病控制率为78.6%，对照组为75%，差异无统计学意义(P>0.05)；易瑞沙的不良反应以一过性食欲减退、轻度皮疹和腹泻为主，研究组的一过性食欲减退和轻度皮疹发生率分别为32.1%和39.3%，明显低于对照组的60.7%和67.9%，差异有统计学意义(P<0.05)；两组患者的1年生存率分别为50.0%和39.3%，差异无统计学意义(P>0.05)。结论阿司匹林小剂量口服联合易瑞沙比单用易瑞沙治疗非小细胞肺癌具有更好的临床疗效，阿司匹林可以降低肿瘤患者的血液高凝状态，提高肿瘤治疗的有效率、生存期，能够降低肿瘤进展时间，从而提高肿瘤患者的生活质量。
展开▼
